DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...
Zacks Investment Research on MSN
Dexcom stock falls despite Q4 earnings beat, G7 rollout drives growth
DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...
StockStory.org on MSN
DexCom (NASDAQ:DXCM) exceeds Q4 CY2025 expectations
Medical device company DexCom (NASDAQ:DXCM) announced in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...
(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results